INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
Public company

Gossamer Bio, Inc.

GOSSCIK 0001728117

EDGAR filingsOpen in network
Price$9.77
1 year-94.8%
Disclosed transactions60
Buys / sells0 / 0
Max Insider Score9
Connections with evidence12

GOSS · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
MS
Milligan SandraDirector
GOSSGossamer Bio, Inc.
Grant or award
A—
10.0K sh
Sep 23, 2026Sep 25, 2026

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Cox Russell J.Director · Sep 25, 2026
  • ← Insider ofevidence
    Daniel Thomas ODirector · Sep 25, 2026
  • ← Insider ofevidence
    Ciongoli Gregory AustinDirector · Sep 25, 2026
  • ← Insider ofevidence
traded Sep 23, 2026
+2d
SEC FORM 4

Evidence

9
DO
Daniel Thomas ODirector
GOSSGossamer Bio, Inc.
Grant or award
A—
10.0K sh
Sep 23, 2026Sep 25, 2026
traded Sep 23, 2026
+2dSEC FORM 4

Evidence

9
QD
Quisel John DDirector
GOSSGossamer Bio, Inc.
Grant or award
A—
10.0K sh
Sep 23, 2026Sep 25, 2026
traded Sep 23, 2026
+2dSEC FORM 4

Evidence

9
DS
Drynan SkyeDirector
GOSSGossamer Bio, Inc.
Grant or award
A—
10.0K sh
Sep 23, 2026Sep 25, 2026
traded Sep 23, 2026
+2dSEC FORM 4

Evidence

9
CJ
Cox Russell J.Director
GOSSGossamer Bio, Inc.
Grant or award
A—
10.0K sh
Sep 23, 2026Sep 25, 2026
traded Sep 23, 2026
+2dSEC FORM 4

Evidence

9
ND
Nathan Steven DDirector
GOSSGossamer Bio, Inc.
Grant or award
A—
10.0K sh
Sep 23, 2026Sep 25, 2026
traded Sep 23, 2026
+2dSEC FORM 4

Evidence

9
CA
Ciongoli Gregory AustinDirector
GOSSGossamer Bio, Inc.
Grant or award
A—
30.0K sh
Sep 23, 2026Sep 25, 2026
traded Sep 23, 2026
+2dSEC FORM 4

Evidence

9
GB
Giraudo BryanCOO/CFO
GOSSGossamer Bio, Inc.
Grant or award
A$25K
25 sh
Aug 24, 2026Aug 26, 2026
traded Aug 24, 2026
+2dSEC FORM 4

Evidence

9
PC
Peterson CarynChief Development Officer
GOSSGossamer Bio, Inc.
Grant or award
A—
5.80M sh
Aug 24, 2026Aug 26, 2026
traded Aug 24, 2026
+2dSEC FORM 4

Evidence

9
GB
Giraudo BryanCOO/CFO
GOSSGossamer Bio, Inc.
Grant or award
A—
5.80M sh
Aug 24, 2026Aug 26, 2026
traded Aug 24, 2026
+2dSEC FORM 4

Evidence

9
SP
Smith Robert Paul JRChief Commercial Officer
GOSSGossamer Bio, Inc.
Grant or award
A—
5.80M sh
Aug 24, 2026Aug 26, 2026
traded Aug 24, 2026
+2dSEC FORM 4

Evidence

9
ND
Nathan Steven DDirector
GOSSGossamer Bio, Inc.
Grant or award
A—
115.0K sh
Jun 4, 2026Jun 5, 2026
traded Jun 4, 2026
+1dSEC FORM 4

Evidence

9
MS
Milligan SandraDirector
GOSSGossamer Bio, Inc.
Grant or award
A—
115.0K sh
Jun 4, 2026Jun 5, 2026
traded Jun 4, 2026
+1dSEC FORM 4

Evidence

9
DS
Drynan SkyeDirector
GOSSGossamer Bio, Inc.
Grant or award
A—
115.0K sh
Jun 4, 2026Jun 5, 2026
traded Jun 4, 2026
+1dSEC FORM 4

Evidence

9
AR
Aranda RichardChief Medical Officer
GOSSGossamer Bio, Inc.
Grant or award
A—
157.5K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
AR
Aranda RichardChief Medical Officer
GOSSGossamer Bio, Inc.
Grant or award
A—
20.0K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
AR
Aranda RichardChief Medical Officer
GOSSGossamer Bio, Inc.
Grant or award
A—
40.0K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
AR
Aranda RichardChief Medical Officer
GOSSGossamer Bio, Inc.
Grant or award
A—
9,167 sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
PC
Peterson CarynEVP, Regulatory Affairs
GOSSGossamer Bio, Inc.
Disposition to issuer
D—
506.3K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
PC
Peterson CarynEVP, Regulatory Affairs
GOSSGossamer Bio, Inc.
Disposition to issuer
D—
375.0K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
PC
Peterson CarynEVP, Regulatory Affairs
GOSSGossamer Bio, Inc.
Disposition to issuer
D—
125.0K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
PC
Peterson CarynEVP, Regulatory Affairs
GOSSGossamer Bio, Inc.
Disposition to issuer
D—
157.5K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
PC
Peterson CarynEVP, Regulatory Affairs
GOSSGossamer Bio, Inc.
Disposition to issuer
D—
157.5K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
PC
Peterson CarynEVP, Regulatory Affairs
GOSSGossamer Bio, Inc.
Disposition to issuer
D—
126.7K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
AR
Aranda RichardChief Medical Officer
GOSSGossamer Bio, Inc.
Grant or award
A—
126.7K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
PC
Peterson CarynEVP, Regulatory Affairs
GOSSGossamer Bio, Inc.
Disposition to issuer
D—
21.2K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
PC
Peterson CarynEVP, Regulatory Affairs
GOSSGossamer Bio, Inc.
Disposition to issuer
D—
9,167 sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
PC
Peterson CarynEVP, Regulatory Affairs
GOSSGossamer Bio, Inc.
Disposition to issuer
D—
32.3K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
PC
Peterson CarynEVP, Regulatory Affairs
GOSSGossamer Bio, Inc.
Grant or award
A—
506.3K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
PC
Peterson CarynEVP, Regulatory Affairs
GOSSGossamer Bio, Inc.
Grant or award
A—
440.0K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
PC
Peterson CarynEVP, Regulatory Affairs
GOSSGossamer Bio, Inc.
Grant or award
A—
375.0K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
PC
Peterson CarynEVP, Regulatory Affairs
GOSSGossamer Bio, Inc.
Grant or award
A—
125.0K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
PC
Peterson CarynEVP, Regulatory Affairs
GOSSGossamer Bio, Inc.
Grant or award
A—
157.5K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
PC
Peterson CarynEVP, Regulatory Affairs
GOSSGossamer Bio, Inc.
Grant or award
A—
157.5K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
PC
Peterson CarynEVP, Regulatory Affairs
GOSSGossamer Bio, Inc.
Grant or award
A—
126.7K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
PC
Peterson CarynEVP, Regulatory Affairs
GOSSGossamer Bio, Inc.
Grant or award
A—
21.2K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
PC
Peterson CarynEVP, Regulatory Affairs
GOSSGossamer Bio, Inc.
Grant or award
A—
18.8K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
PC
Peterson CarynEVP, Regulatory Affairs
GOSSGossamer Bio, Inc.
Grant or award
A—
9,167 sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
GB
Giraudo BryanCOO/CFO
GOSSGossamer Bio, Inc.
Disposition to issuer
D—
638.0K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
GB
Giraudo BryanCOO/CFO
GOSSGossamer Bio, Inc.
Disposition to issuer
D—
543.8K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
GB
Giraudo BryanCOO/CFO
GOSSGossamer Bio, Inc.
Disposition to issuer
D—
181.3K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
GB
Giraudo BryanCOO/CFO
GOSSGossamer Bio, Inc.
Disposition to issuer
D—
211.5K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
GB
Giraudo BryanCOO/CFO
GOSSGossamer Bio, Inc.
Disposition to issuer
D—
211.5K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
GB
Giraudo BryanCOO/CFO
GOSSGossamer Bio, Inc.
Disposition to issuer
D—
176.7K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
GB
Giraudo BryanCOO/CFO
GOSSGossamer Bio, Inc.
Disposition to issuer
D—
100.0K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
GB
Giraudo BryanCOO/CFO
GOSSGossamer Bio, Inc.
Disposition to issuer
D—
60.0K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
GB
Giraudo BryanCOO/CFO
GOSSGossamer Bio, Inc.
Disposition to issuer
D—
47.7K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
GB
Giraudo BryanCOO/CFO
GOSSGossamer Bio, Inc.
Grant or award
A—
638.0K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
GB
Giraudo BryanCOO/CFO
GOSSGossamer Bio, Inc.
Grant or award
A—
543.8K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
GB
Giraudo BryanCOO/CFO
GOSSGossamer Bio, Inc.
Grant or award
A—
181.3K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
GB
Giraudo BryanCOO/CFO
GOSSGossamer Bio, Inc.
Grant or award
A—
211.5K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
GB
Giraudo BryanCOO/CFO
GOSSGossamer Bio, Inc.
Grant or award
A—
176.7K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
GB
Giraudo BryanCOO/CFO
GOSSGossamer Bio, Inc.
Grant or award
A—
100.0K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
GB
Giraudo BryanCOO/CFO
GOSSGossamer Bio, Inc.
Grant or award
A—
60.0K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
GB
Giraudo BryanCOO/CFO
GOSSGossamer Bio, Inc.
Grant or award
A—
96.7K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
AR
Aranda RichardChief Medical Officer
GOSSGossamer Bio, Inc.
Disposition to issuer
D—
562.5K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
AR
Aranda RichardChief Medical Officer
GOSSGossamer Bio, Inc.
Disposition to issuer
D—
40.0K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
GB
Giraudo BryanCOO/CFO
GOSSGossamer Bio, Inc.
Grant or award
A—
211.5K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
PC
Peterson CarynEVP, Regulatory Affairs
GOSSGossamer Bio, Inc.
Disposition to issuer
D—
22.8K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

9
SP
Smith Robert Paul JRChief Commercial Officer
GOSSGossamer Bio, Inc.
Grant or award
A—
562.5K sh
Mar 19, 2026Mar 20, 2026
traded Mar 19, 2026
+1dSEC FORM 4

Evidence

Quisel John D
Director · Sep 25, 2026
  • ← Insider ofevidence
    Nathan Steven DDirector · Jun 5, 2026
  • ← Insider ofevidence
    Drynan SkyeDirector · Jun 5, 2026
  • ← Insider ofevidence
    Milligan SandraDirector · Jun 5, 2026
  • ← Insider ofevidence
    Giraudo BryanCOO/CFO · Mar 20, 2026
  • ← Insider ofevidence
    Aranda RichardChief Medical Officer · Mar 20, 2026
  • ← Insider ofevidence
    Smith Robert Paul JRChief Commercial Officer · Mar 20, 2026
  • ← Insider ofevidence
    Peterson CarynEVP, Regulatory Affairs · Mar 20, 2026